Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.62 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31535625 | 0.82 | KMT2A (0.59) | KMT2AMEN1MKNK1MKNK2POLB | |
| SCHEMBL12520958 | 0.81 | CYP1A2 (0.73) | KMT2AMEN1ALDH1A1USP2LMNA | |
| SCHEMBL34462772 | 0.80 | HTR1A (0.57) | KMT2AMEN1MKNK1MKNK2POLB | |
| SCHEMBL30278163 | 0.80 | KMT2A (0.58) | KMT2AMEN1MKNK1MKNK2POLB | |
| SCHEMBL6168420 | 0.79 | HTR2A (0.49) | KMT2AMEN1POLBSLC2A1RAD52 | |
| SCHEMBL28046116 | 0.79 | HTR2A (0.64) | KMT2AMEN1MKNK1MKNK2POLB | |
| SCHEMBL29244496 | 0.79 | KMT2A (0.55) | KMT2AMEN1MKNK1MKNK2POLB | |
| SCHEMBL30278225 | 0.79 | KMT2A (0.55) | KMT2AMEN1MKNK1MKNK2POLB | |
| SCHEMBL20557915 | 0.78 | HTR1A (0.63) | KMT2AMEN1MKNK1MKNK2POLB | |
| SCHEMBL30579382 | 0.78 | HTR1A (0.63) | KMT2AMEN1MKNK1MKNK2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103619835-B | Novel Pyrimidine Derivatives | Novija Research (SE) | 2016-11-30 | — | — | CN | disclosed |
| EP-2688883-B1 | PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2688883-B1 | PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| US-9006241-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-04-14 | — | — | US | disclosed |
| US-9006241-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-04-14 | — | — | US | disclosed |
| US-8927547-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-01-06 | — | — | US | disclosed |
| US-8927547-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-01-06 | — | — | US | disclosed |
| CN-103619835-A | Novel pyrimidine derivatives | CHEMILIA AB | 2014-03-05 | — | — | CN | disclosed |
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| EP-2571867-A1 | NOVEL PYRIMIDINE DERIVATIVES | Chemilia AB (SE) | 2013-03-27 | — | — | EP | disclosed |
| WO-2012127032-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012127032-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2012-09-27 | — | — | WO | disclosed |
| EP-2502924-A1 | Novel pyrimidine derivatives | Chemilia AB (SE) | 2012-09-26 | — | — | EP | disclosed |
| EP-2502924-A1 | Novel pyrimidine derivatives | Chemilia AB (SE) | 2012-09-26 | — | — | EP | disclosed |
| EP-2395001-A1 | Novel pyrimidine derivatives | Chemilia AB (SE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2395001-A1 | Novel pyrimidine derivatives | Chemilia AB (SE) | 2011-12-14 | — | — | EP | disclosed |
| WO-2011144742-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011144742-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | KMT2A 2089/4885MEN1 3978/4885MKNK1 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.